Phaseline

Companies › Wanbangde Pharmaceutical Group

Wanbangde Pharmaceutical Group: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 4, 1 Phase 2; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ginkgo leaf dropping pill
Ginkgo biloba extract (neuroprotection and cognitive enhancement)
–Phase 4Cognitive Impairment After Brain InjuryDec 2026
Huperzine A Controlled-Release Tablets
Acetylcholinesterase inhibitor
ACHEPhase 4Cognitive Impairment After Brain Injury; Alzheimer DementiaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06704334Ginkgo leaf dropping pillPhase 4Cognitive Impairment After Brain InjuryNeurologyDec 2026
NCT06704334Huperzine A Controlled-Release TabletsPhase 4Cognitive Impairment After Brain InjuryNeurologyDec 2026
NCT07066826Huperzine A Controlled-Release TabletsPhase 2Alzheimer DementiaNeurologyAug 2028

Targets

ACHE (1)

Companies with the same targets

Supernus Pharmaceuticals Inventage Lab. Alpha Cognition

Companies built like this

Alpha Cognition Pharmasoft Suven Life Sciences Bigespas JYAMS PET Research & Development

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.